Kee Song Bio-Technology Holdings (ROCO:1258) EBIT : NT$222 Mil (TTM As of Mar. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Kee Song Bio-Technology Holdings EBIT?

Kee Song Bio-Technology Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was NT$81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was NT$222 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kee Song Bio-Technology Holdings's annualized ROC % for the quarter that ended in Mar. 2023 was 11.59%. Kee Song Bio-Technology Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 22.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kee Song Bio-Technology Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 12.89%.

Kee Song Bio-Technology Holdings EBIT Historical Data

The historical data trend for Kee Song Bio-Technology Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kee Song Bio-Technology Holdings EBIT Chart

Kee Song Bio-Technology Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-122.78

-108.45

36.80

119.06

176.79

Kee Song Bio-Technology Holdings Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT	Get a 7-Day Free Trial															36.06	72.52	-42.43	110.64	81.05

Competitive Comparison of Kee Song Bio-Technology Holdings's EBIT

For the Packaged Foods subindustry, Kee Song Bio-Technology Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kee Song Bio-Technology Holdings's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kee Song Bio-Technology Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kee Song Bio-Technology Holdings's EV-to-EBIT falls into.

Kee Song Bio-Technology Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$222 Mil.

Kee Song Bio-Technology Holdings (ROCO:1258) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kee Song Bio-Technology Holdings's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	275.112 * ( 1 - 27.55% )	/	( (1747.675	+	1690.509)	/ 2 )
=	199.318644	/	1719.092
=	11.59 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2341.95	-	410.689	-	( 342.8	-	max(0, 657.031	-	840.617	+	342.8	))
=	1747.675

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2266.869	-	361.302	-	( 344.276	-	max(0, 571.27	-	786.328	+	344.276	))
=	1690.509

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kee Song Bio-Technology Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Mar. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	324.192	/	( ( (1380.682 + max(50.95, 0))	+	(1360.808 + max(52.147, 0)) )	/	2 )
=	324.192	/	( ( 1431.632	+	1412.955 )	/	2 )
=	324.192	/	1422.2935
=	22.79 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(171.034	+	257.821	+	32.784)	-	(410.689	+	0	+	-1.1368683772162E-13)
=	50.95

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(143.753	+	234.097	+	35.599)	-	(361.302	+	0	+	0)
=	52.147

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kee Song Bio-Technology Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2023 )
	=	221.782	/	1720.256
	=	12.89 %

Kee Song Bio-Technology Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Kee Song Bio-Technology Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kee Song Bio-Technology Holdings (ROCO:1258) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Kee Song Bio-Technology Holdings Ltd (ROCO:1258) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Songjiang Road, 104, 8th Floor, No. 51, Zhongshan District, Taipei, TWN, 104

Website

https://www.keesongbiotech.com

Kee Song Bio-Technology Holdings Ltd is engaged in the processing and distribution of meat products. This includes poultry, production, and sale of chicken as well as the trade of frozen meat and prepared food. It has two reportable segments; the Poultry and processing distribution segment which is engaged in the business of importing, slaughtering, wholesaling, and retailing poultry and consumable goods of all kinds; and the Poultry farming segment involved in the business of poultry farming. It derives a majority of its revenue from the poultry farming segment.

Kee Song Bio-Technology Holdings (ROCO:1258) Headlines

No Headlines